AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end.
Author: Rebecca Robbins
Advertisements
{
"slotId": "6845006044",
"unitType": "responsive",
"resize": "auto"
}